Bevacizumab	O
and	O
irinotecan	O
therapy	O
in	O
glioblastoma	B-Cancer
multiforme	I-Cancer
:	O
a	O
series	O
of	O
13	O
cases	O
.	O

OBJECT	O
:	O
Endothelial	B-Cell
proliferation	O
has	O
been	O
recognized	O
as	O
a	O
marker	O
of	O
high	B-Cancer
-	I-Cancer
grade	I-Cancer
or	O
aggressive	B-Cancer
glioma	I-Cancer
.	O

Bevacizumab	O
is	O
a	O
humanized	O
immunoglobulin	O
G1	O
monoclonal	O
antibody	O
to	O
vascular	O
endothelial	O
growth	O
factor	O
that	O
has	O
been	O
shown	O
to	O
have	O
activity	O
in	O
malignant	B-Cancer
gliomas	I-Cancer
when	O
combined	O
with	O
irinotecan	O
.	O

The	O
authors	O
report	O
on	O
a	O
case	O
series	O
of	O
13	O
patients	O
with	O
recurrent	O
heavily	O
pretreated	O
malignant	B-Cancer
glioma	I-Cancer
that	O
was	O
treated	O
with	O
the	O
combination	O
of	O
bevacizumab	O
and	O
irinotecan	O
.	O

METHODS	O
:	O
Standard	O
therapy	O
with	O
primary	O
resection	O
followed	O
by	O
adjuvant	O
chemotherapy	O
and	O
radiation	O
had	O
failed	O
in	O
all	O
patients	O
.	O

The	O
median	O
number	O
of	O
therapies	O
applied	O
,	O
including	O
initial	O
surgery	O
,	O
was	O
5	O
(	O
range	O
3	O
-	O
7	O
therapies	O
)	O
.	O

Nine	O
patients	O
were	O
started	O
on	O
bevacizumab	O
at	O
a	O
dose	O
of	O
5	O
mg	O
/	O
m2	O
every	O
2	O
weeks	O
.	O

Four	O
patients	O
received	O
bevacizumab	O
at	O
a	O
dose	O
of	O
10	O
mg	O
/	O
m2	O
;	O
irinotecan	O
was	O
given	O
at	O
a	O
dose	O
of	O
125	O
mg	O
/	O
m2	O
every	O
week	O
for	O
3	O
weeks	O
.	O

RESULTS	O
:	O
Of	O
the	O
13	O
treated	O
patients	O
,	O
10	O
(	O
77	O
%	O
)	O
had	O
a	O
radiologically	O
demonstrated	O
partial	O
response	O
and	O
3	O
(	O
23	O
%	O
)	O
had	O
stable	O
disease	O
.	O

Six	O
patients	O
(	O
46	O
%	O
)	O
had	O
a	O
clinical	O
response	O
.	O

The	O
median	O
time	O
to	O
disease	O
progression	O
while	O
on	O
treatment	O
was	O
24	O
weeks	O
.	O

The	O
median	O
overall	O
survival	O
was	O
27	O
weeks	O
.	O

The	O
disease	O
progressed	O
in	O
8	O
patients	O
,	O
despite	O
an	O
initial	O
response	O
.	O

Five	O
patients	O
are	O
still	O
responding	O
to	O
therapy	O
.	O

Six	O
of	O
the	O
8	O
patients	O
whose	O
disease	O
progressed	O
have	O
died	O
.	O

Bevacizumab	O
was	O
discontinued	O
in	O
2	O
patients	O
because	O
of	O
nonfatal	O
intracranial	B-Immaterial_anatomical_entity
bleeding	O
.	O

CONCLUSIONS	O
:	O
The	O
combination	O
of	O
bevacizumab	O
and	O
irinotecan	O
is	O
safe	O
and	O
has	O
excellent	O
activity	O
even	O
in	O
this	O
relapsed	O
,	O
heavily	O
pretreated	O
population	O
of	O
patients	O
with	O
high	B-Cancer
-	I-Cancer
grade	I-Cancer
malignant	I-Cancer
glioma	I-Cancer
,	O
most	O
of	O
whom	O
would	O
not	O
be	O
candidates	O
for	O
clinical	O
trials	O
.	O

